Login to Your Account



After Phase III Melanoma Failure

Vical: Cutbacks, Refocus Aim to Tackle Infectious Diseases

By Randy Osborne
Staff Writer

Monday, August 26, 2013
In a wagon-circling move typical after Phase III setbacks such as befell Vical Inc.'s compound for metastatic melanoma earlier this month, the company said it will cut its work force by about 39 percent, or 47 employees, leaving 74 still aboard, as the Allovectin project is abandoned and efforts turn to infectious-disease vaccine programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription